In summary, TP53 gene mutation may increase the TMB and lead to a TME shift towards suppressed angiogenesis and increased mesenchymal features, thereby influencing the progression and treatment outcomes of HCC and EC. Here, TP53 is linked to hepatocellular carcinoma.